| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11899-019-00539-3 |
| P698 | PubMed publication ID | 31512151 |
| P2093 | author name string | Herbert Eradat | |
| P2860 | cites work | miR-15 and miR-16 induce apoptosis by targeting BCL2 | Q24536069 |
| Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia | Q24539231 | ||
| Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up | Q27851444 | ||
| Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia | Q28087672 | ||
| Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia | Q28206302 | ||
| Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene | Q28216381 | ||
| Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia | Q28256227 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data | Q31096565 | ||
| Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial | Q33419580 | ||
| Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies | Q33422543 | ||
| Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study | Q33432228 | ||
| Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study | Q33438428 | ||
| Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. | Q33794311 | ||
| Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. | Q33873343 | ||
| Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. | Q34008866 | ||
| Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation | Q34245495 | ||
| Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 | ||
| Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 | ||
| Chronic lymphocytic leukemia: a clinical review | Q35476648 | ||
| Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
| Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients | Q36273066 | ||
| A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia | Q36276017 | ||
| The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. | Q37035832 | ||
| How we treat Richter syndrome | Q37636962 | ||
| Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases | Q37921609 | ||
| Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination? | Q38850312 | ||
| Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies | Q38996888 | ||
| Venetoclax and obinutuzumab in chronic lymphocytic leukemia | Q42348732 | ||
| Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial | Q47300370 | ||
| Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy | Q47664480 | ||
| Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. | Q48189581 | ||
| The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. | Q51014811 | ||
| Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma. | Q51280033 | ||
| Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia. | Q53255566 | ||
| Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia | Q57169180 | ||
| Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL | Q60301984 | ||
| Involvement of the bcl-2 gene in human follicular lymphoma | Q69870224 | ||
| Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial | Q83441006 | ||
| Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial | Q90986748 | ||
| P433 | issue | 5 | |
| P921 | main subject | chronic lymphocytic leukemia | Q1088156 |
| P304 | page(s) | 469-476 | |
| P577 | publication date | 2019-10-01 | |
| P1433 | published in | Current hematologic malignancy reports | Q26842233 |
| P1476 | title | Venetoclax for the Treatment of Chronic Lymphocytic Leukemia | |
| P478 | volume | 14 |
Search more.